Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Among research news last week, Gilead Sciences released positive new Phase III data on progression fee survival for its Trodelvy plus Keytruda in breast cancer. Roivant company Immunovant last week ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Jacquie Ross; Senior Vice President - Treasury, Investor Relations; Gilead Sciences Inc. Daniel O'Day; Chairman, Chief Executive Officer; Gilead Sciences Inc. Johann ...

Oppenheimer lowered the firm’s price target on Gilead (GILD) to $125 from $132 and keeps an Outperform rating on the shares. The firm notes ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead’s HIV product sales, which make up the bulk of its revenue, increased 6% YoY to $4.6 billion, but fell 16% ...

Gain key insights from Gilead Sciences' Q1 2025 earnings call, featuring strong HIV sales, Lenacapavir launch updates, and market trends shaping ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Gilead Sciences on Thursday reported slightly higher-than-expected quarterly earnings on flat revenue, as higher sales of ...